XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.2

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands, shares in Millions	1 Months Ended				3 Months Ended				6 Months Ended		12 Months Ended
	Jan. 31, 2022	Aug. 31, 2020	Mar. 31, 2020	Aug. 31, 2018	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2020	Mar. 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2018	Dec. 31, 2021	Dec. 31, 2020
Other Commitments [Line Items]
Gain (loss) on strategic investment									$ (158)	$ 323
Research and development					$ 75,646	$ 56,935			204,501	113,908
Restricted cash					5,770	$ 5,770			5,770	$ 5,770		$ 5,770	$ 5,770
Letter of Credit | Corporate Credit Card Program
Other Commitments [Line Items]
Restricted cash					2,000				2,000
Letter of Credit | Fleet Program
Other Commitments [Line Items]
Restricted cash					400				400
Cersci Therapeutics
Other Commitments [Line Items]
Upfront consideration and transaction costs		$ 52,800
Upfront payment		$ 44,300
Upfront payment conditions		The Company incurred an aggregate of $52.8 million in upfront consideration and transaction costs, of which, $44.3 million was paid through the issuance of approximately 1.2 million shares of the Company’s common stock.
Cersci Therapeutics | Research And Development Expense Member
Other Commitments [Line Items]
Assets acquisition and upfront payment							$ 45,700
Stoke Therapeutics, Inc. [Member]
Other Commitments [Line Items]
Upfront payment	$ 60,000
Mile stone payments payable	$ 907,500
License Agreements | Neuren | North America
Other Commitments [Line Items]
Upfront payment			$ 10,000
Upfront license fee				$ 10,000
License Agreements | Neuren | Research And Development Expense Member | North America
Other Commitments [Line Items]
Upfront payment								$ 10,000			$ 10,000
Maximum
Other Commitments [Line Items]
Mile stone payments payable					$ 3,100,000				$ 3,100,000
Maximum | Cersci Therapeutics
Other Commitments [Line Items]
Common stock issuance		1.2
Maximum | Cersci Therapeutics | Development Commercialization and Sales Milestones
Other Commitments [Line Items]
Compensation expense related to mergers to former holders		$ 887,000
Maximum | License Agreements | Neuren | North America
Other Commitments [Line Items]
Mile stone payments payable			$ 515,000	$ 455,000				$ 515,000

X

- Definition

Collaborative arrangements assets acquisition and upfront payment.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative arrangements non-cash upfront payment.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsNonCashUpfrontPayment
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative Arrangements Upfront consideration and transaction Payment.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsUpfrontConsiderationAndTransactionPayment
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative arrangements upfront license fee.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsUpfrontLicenseFee
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative arrangements upfront payment.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsUpfrontPayment
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative Arrangements Upfront payment description.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsUpfrontPaymentDescription
Namespace Prefix:	acad_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative arrangements upfront payment shares issued.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsUpfrontPaymentSharesIssued
Namespace Prefix:	acad_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Compensation expense related to mergers to former holders.

+ References

No definition available.

+ Details

Name:	acad_CompensationExpenseRelatedToMergersToFormerHolders
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.

+ References

No definition available.

+ Details

Name:	us-gaap_ContractualObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of realized and unrealized gain (loss) on investment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(c),9(a))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

+ Details

Name:	us-gaap_GainLossOnInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 210
-Section 45
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580

+ Details

Name:	us-gaap_RestrictedCashNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Details

Name:	us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=acad_CorporateCreditCardProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=acad_FleetProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=acad_CersciTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=acad_StokeTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=acad_LicenseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=acad_NeurenPharmaceuticalsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=acad_DevelopmentCommercializationAndSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: